Compare GPI & ATRC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GPI | ATRC |
|---|---|---|
| Founded | 1995 | 2000 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Retail-Auto Dealers and Gas Stations | Medical/Dental Instruments |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.0B | 2.5B |
| IPO Year | 1997 | 2005 |
| Metric | GPI | ATRC |
|---|---|---|
| Price | $248.83 | $61.32 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 7 | 7 |
| Target Price | ★ $447.14 | $51.17 |
| AVG Volume (30 Days) | 201.3K | ★ 996.8K |
| Earning Date | 04-30-2026 | 05-05-2026 |
| Dividend Yield | ★ 0.57% | N/A |
| EPS Growth | N/A | ★ 74.74 |
| EPS | ★ 19.50 | 0.18 |
| Revenue | ★ $11,123,721,000.00 | $201,630,000.00 |
| Revenue This Year | $3.41 | $15.27 |
| Revenue Next Year | $3.10 | $12.21 |
| P/E Ratio | ★ $12.69 | $333.08 |
| Revenue Growth | 2.17 | ★ 15.40 |
| 52 Week Low | $246.31 | $25.36 |
| 52 Week High | $461.27 | $61.48 |
| Indicator | GPI | ATRC |
|---|---|---|
| Relative Strength Index (RSI) | 39.26 | 77.65 |
| Support Level | $249.54 | $26.95 |
| Resistance Level | $343.25 | N/A |
| Average True Range (ATR) | 11.20 | 1.90 |
| MACD | -2.41 | 0.07 |
| Stochastic Oscillator | 6.16 | 80.61 |
Group 1 owns and operates 32 collision centers and over 250 automotive dealerships in the US and the UK, offering 36 brands of automobiles altogether. Slightly over half of the stores are in the US with locations mostly in metropolitan areas in 17 states in the Northeast, Southeast, Midwest, and California. Texas alone contributed 31.6% of new-vehicle unit volume in 2025 and the UK 27.6%. Texas, Massachusetts, and California combined was 45.4%. Revenue in 2025 totaled $22.6 billion. The firm entered the UK in 2007 and has 106 stores there contributing about 26% of total revenue. Group 1 was founded in 1995 and is based in Houston.
AtriCure Inc is an innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, and sells its products to medical centers through its direct sales force and distributors. Its product line includes Cryo, Soft Tissue Dissection, RF Ablation, Pacing and Sensing, and others. Geographically, it generates a majority of its revenue from the United States. Cardiac ablation and left atrial appendage management (LAAM) products are used by physicians during open-heart and minimally invasive surgical procedures. Pain management solutions are used by physicians to freeze nerves during cardiothoracic or thoracic surgical procedures.